Samuel Cytryn, MD, of Memorial Sloan Kettering Cancer Center, discusses the December 2024 FDA approval of tislelizumab in combination with chemotherapy for patients with PD-L1 positive advanced metastatic gastric and gastroesophageal junction cancers. Dr. Cytryn examines key findings from the RATIONALE-305 trial, which demonstrated improved overall and progression-free survival, reinforcing the role of PD-1 inhibitors in this population.
GI Oncology Now
The leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies
Advertisement
Latest News
Dr. Pant describes the improved DOR and median OS seen with the treatment, and discusses the ongoing phase 3 trial.
The approval is based on positive results of the CodeBreaK300 trial, which demonstrated an improvement in PFS.
The peripheral blood transcriptome of NET patients showed differential enrichment of 30 systemic cancer hallmarks.
Drs. Finn and Yopp discuss adjuvant therapy in HCC following surgical resection in a review of data from IMbrave050.
Adding a taxane to the standard regimen of gemcitabine/cisplatin does not improve OS in patients with newly diagnosed BTC.
Drs. Finn and Yopp discuss the IMbrave050 study for early-stage HCC, including the trial design, results, and implications.
A recent study reviewed global disparities in gastric cancer screening, finding limited research about screening feasibility.
A recent study showed evidence that HBV infection facilitates drug resistance in cancer treatment medications.
Tislelizumab is a monoclonal antibody with a high affinity and binding specificity against programmed cell death protein 1.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
Advertisement
Roundtable Discussions
Oncology Brothers Event Coverage
GI Oncology Now has exclusive coverage of Advancement in Oncology: Today’s Data for Tomorrow’s Practice, the first event co-hosted by The Oncology Brothers and Mashup Media. Review the breakthrough data on gastrointestinal cancers presented at the event and insights from esteemed experts that bridge the gap between research and practice for community oncologists.
Conference Coverage
The latest news and research updates in GI cancer treatment from the ESMO Congress 2024
The latest news and research updates in GI cancer treatment from the ASCO 2024 Annual Meeting
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
GI Oncology Now reviews education from ISGIO 2023, featuring the latest advances in the field of GI cancer research.
Expert Interviews
Advertisement
Advertisement
Editorial Advisory Board
Christopher Lieu, MDEditor | Co-Director of Gastrointestinal Medical Oncology at University of Colorado Medicine
Benjamin Weinberg, MD, FACPEditor | Associate Professor of Medicine at Lombardi Comprehensive Cancer Center
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.